

## Paralysis Case and Contact Spread of Recombinant Vaccine-derived Poliovirus, Spain

**To the Editor:** The World Health Organization Polio Eradication Initiative has reduced to 4 the number of countries with endemic transmission of wild polioviruses and has reported the widespread circulation of polioviruses that have evolved from attenuated vaccine (oral poliovirus vaccine [OPV]), so-called vaccine-derived polioviruses (VDPVs) (1,2). VDPVs can reportedly replicate in immunocompromised persons, in whom they produce paralysis, and can spread to contacts and produce paralytic polio in immunocompetent but incompletely immunized persons; these viruses can even cause some polio outbreaks in areas with a low level of vaccination coverage (2). When VDPVs are detected, a careful follow-up of VDPV cases and contacts is essential if spread is to be avoided. Because point mutations or recombination events have been associated with reversion to neurovirulence transmission and thus a greater probability of outbreaks (2), meticulous molecular studies of the detected strains are recommended.

Spain progressively adopted vaccination with OPV for children in 2004. As a consequence, the incidence of vaccine-like poliovirus detection in recently vaccinated children, which was relatively common up to that time (51 isolates in 2003) (3), began to decrease (15 isolates in 2004 and none in 2005 except the case described here). In July 2005, a 14-month-old boy from Morocco with residual paralysis and major histocompatibility class II immunodeficiency was reported through the Spanish Acute Flaccid Paralysis Surveillance System. The patient had received 2 OPV doses at birth and at 6 months of age in Morocco; 8 months later, meningo-

encephalitis developed. The case was immediately considered suspicious and was therefore monitored at least monthly until the boy died. Sampling was conducted, coinciding with his visits to the hospital to receive therapy with immunoglobulin ( $\gamma$  globulin 0.5 g/kg). His contacts were studied, environmental surveillance was conducted, and molecular analysis of all detected viruses was performed. Laboratory methods for virus detection and characterization, including 10 new reverse-transcription-PCRs designed to cover the entire genome, are detailed in the Table.

Serotype 2 VDPVs were detected in all 10 stool samples of the patient with residual paralysis for 6 months, until he died, and in 3 of the 7 family contacts analyzed (father and 2 brothers, 11 and 13 years of age, none with confirmed previous vaccination). One of the contacts, considered immunocompetent, shed virus for 216 days (5 fecal samples in which 5 complete genomes were obtained and 1 additional fecal sample in which virus capsid protein 1 [VP1] could be amplified); a stool sample collected on day 284 was negative. Technical problems delayed sewage sampling. When sewage from the area in which the patient and positive contacts lived was sampled on February 8, 2006, no polioviruses were detected; however, an echovirus 30 was detected. Poliovirus viral load fluctuated ( $10^6$ – $10^9$  copies/mL in the paralysis-affected person), decreasing after each immunoglobulin therapy dose (Figure 1 in online Technical Appendix, available from [www.cdc.gov/EID/content/14/11/1807-Techapp.pdf](http://www.cdc.gov/EID/content/14/11/1807-Techapp.pdf)). The corresponding level was  $<10^5$  in the contacts. The highest value of viral load was recorded in the patient's final sample, taken before he died. Homology of the VP1 gene with respect to the original vaccine PV2 fluctuated from 97.8% to 98.6% in the case samples but remained constant (98.4%) in the contact samples (Figure 1 in online Technical Appendix). All

studied polioviruses featured the following nucleotide substitutions in the 5' untranslated region: G309A, T344C, T355C, T398C, A481G, T500C, and T743C (Figure 2 in online Technical Appendix). Furthermore, the final sample from the patient had A476C, G505T, T588A, and A738C. Several nucleotide substitutions detected in VP1–4 were common to all samples (Figure 2 in online Technical Appendix); 5 resulted in amino acid changes, including T2909C (VP1 I143T) and G3277A (VP1 V266I). All samples contained 2 noncontiguous recombination fragments Sabin 2/Sabin 1 in the nonstructural genes, including the entire 3C gene and the 3' half of the 3D-pol (Figure 2 in online Technical Appendix) as in other reports (7–10). Both fragments, when compared with C species enterovirus, were closely related to Sabin 1 (99.6% and 97.9%, respectively). Specific nucleotide and amino acid comparisons among the isolates are detailed in Figure 3 in the online Technical Appendix.

According to the proposed classification (2), all the detected viruses were iVDPVs (isolated from immunocompromised patients) that spread only to close contacts because they were not detected in local sewage. If we assume that the greater the amount of viral excretion in feces that occurs, the higher number of replicating polioviruses (as well as the potential for greater genetic diversity), the patient had a more active infection (that responded to the therapy) than did the contacts. Fluctuation in homology to the parental OPV strain might be due not only to the calculation method (calculation was made on the basis of the majority-base call at each chromatogram position, and case sequences presented many mixed nucleotide positions) but also to immunotherapy. Treatment appeared to have decreased virus replication, probably by its action mainly on species with greater fitness and higher replication rates (those that were more similar to the original

Table. Laboratory methods used for study of vaccine-derived poliovirus case, Spain, 2005\*

Procedure	Test	Method†	Sample
Sample preparation	Concentration of sewage for detection of enterovirus in the environment	Concentration with negative charge filters (Millipore, Billerica, MA, USA; 0.45 µm) of 20 L of local sewage	E
	RNA purification from samples (before molecular analysis)	MagAttract Virus Mini-Biorobot (QIAGEN GmbH, Hilden, Germany) from 200 µL of stool sample dissolved in water	S
Classic virology techniques	Cellular culture (Biosafety Level 3) for growing PV	LB20 (transgenic mouse), RD (human rhabdomyosarcoma), HEF (human fibroblast), A-549 (ATCC-CCL185)	S, E
	Immunofluorescence of infected cells	Lim-Beyesh-Melnick A-H and RIVM A-G pools	I
Molecular techniques	EV neutralization assay	Antibodies (Chemicon, Temecula, CA, USA)	I
	Molecular EV detection	RT-nested PCR 5' UTR (4)	S, I, E
	Molecular EV quantification	MutaReal EV real-time PCR kit (Immunodiagnostik AG, Bensheim, Germany)	S
	Molecular EV typing	RT-nested PCR in major VP1 region (5)	S, I, E
	PV intratypic characterization	Specific vaccine PV RT-PCR (6)	S, I, E
	PV genome sequencing fragment 1	1s: TAAACACAGCTCTGGGGTTGTA (2–22) 1as: CACCACCCAAGAAGCGGCC (1023–1041) 1ns: GCTCTGGGGTTGTACCCACTCC (9–30) 1nas: TAACTCTGGGCAATTCAACGA (1001–1021)	S, I
	PV genome sequencing fragment 2†	2s: CATGCTAAACTCCCCAAAC (945–963) 2as: AGGTGCGCAACATGATGG (1882–1910)	S, I
	PV genome sequencing fragment 3†	3s: CAGACAATTACCAGTCTCC (1814–1832) 3as: ATTACTAAAAATGCATTGGTTCCC (2518–2541)	S, I
	PV genome sequencing VP1 fragment†	VP1s: ACAACACAGCATTAGTCAAGAGGCTA (2449–2473) VP1as: GGATTTGGACACCAAAACAAAGC (3385–3407)	S, I
	PV genome sequencing fragment 4†	4s: GTGCCACGACCTCCA (3288–3303) 4as: CTTGGGTGCGACATCTCA (4042–4059)	S, I
	PV genome sequencing fragment 5†	5s: TAATCAAAATTATCTCATCACTTGTG (3962–3987) 5as: CATGAGCGAGTACTCCAGA (4872–4889)	S, I
	PV genome sequencing fragment 6†	6s: CTGGCCAGGAGATTCTG (4834–4949) 6as: AAATGATGGAGTTTTGATCGT (5725–5747)	S, I
	PV genome sequencing fragment 7†	7s: AGGCAGGAATAATCTTGAAA (5630–5650) 7as: CTAAGTATGTAGGCAACAAGAT (6164–6185)	S, I
	PV genome sequencing fragment 8†	8s: CAAAAATGATCCCAGGCTCA (6117–6136) 8as: AAACCTACAGGGCATAGATT (6917–6937)	S, I
	PV genome sequencing fragment 9†	9s: CAGGCACATCAATTTTAACTC (6857–6878) 9as: GGTAAATTTTCTTTAATTTCGGGG (7416–7439)	S, I
	Additional PV sequencing primers	447as: CCGGCCCTGAATGCGGC (447–464) 4666s: CCAGACGGAGCAGACATG (4666–4683)	S, I

\*E, local sewage; S, stools; I, isolates; EV, enterovirus; PV, poliovirus; UTR, untranslated region; VP1, virus capsid protein.

†Sense (s) and antisense (as) primers: 5' → 3' sequence (position according to X00595). n, nested. All reverse transcription-PCR (RT-PCR) systems had the same conditions: 5 µL of clinical samples (case) or isolates (contacts) were added to the reaction mixture (final volume 50 µL): AMV/Tfl 1X reaction buffer, 2 mmol/L MgSO<sub>4</sub>, 200 µM each dNTP, 1 µM each primer, 5 U of AMV RT, and 5 U of Tfl DNA polymerase (Access RT-PCR System, Promega, Madison, WI, USA). First RT step of 45 min at 48°C, 2 min at 94°C, 45 cycles of denaturation (94°C, 2 min), annealing (53°C, 1 min), and elongation (68°C, 1 min 30 s).

Sabin strain). As a consequence, treatment might produce a bottleneck that unmasked more divergent species. Both the case and contact strains had intertypic Sabin 1/Sabin 2 recombination in nonstructural genes and also shared most of the nucleotide and amino acid substitutions. However, pathologic changes occurred only in the patient whose immunologic mechanisms were affected and whose viral load was consequently much higher. A recent report (1) suggests that VDPVs can emerge in any country that uses OPV with insufficient vaccine coverage. In a polio-free IPV-user country, poliomyelitis can arise and spread to

contacts who are not properly vaccinated. In the case we present here, the high level of vaccination coverage in Spain and the rapid control of close contacts achieved through the surveillance and control programs prevented virus spread. In the global pre-eradication phase, countries are recommended to change vaccination from OPV to IPV. However, IPV-adopting countries commonly share borders with OPV-adopting countries and residents may travel back and forth; thus, although the probability of VDPV circulation decreases, it does not reduce to zero. Therefore, active surveillance, rapid classification of isolates, and molecu-

lar characterization of the virus are essential.

#### Acknowledgments

We thank the Spanish Poliovirus Surveillance system, in which both the National Epidemiology and Microbiology Centres and autonomous community authorities participate, for detecting the case; the personnel of the National Centre of Microbiology and Son Dureta Hospital for their technical assistance; and Jose Manuel Echevarria for revision of our manuscript.

This research was developed thanks to the Health Minister DGV11429/05-2A and 2B funding.

**Ana Avellón,<sup>1</sup> Maria Cabrerizo,<sup>1</sup>  
Teresa de Miguel, Pilar Pérez-  
Breña, Antonio Tenorio,  
Jose Luis Pérez, Maria Victoria  
Martínez de Aragón,  
and Gloria Trallero**

Author affiliations: Instituto de Salud Carlos III National Centre of Microbiology, Madrid, Spain (A. Avellón, M. Cabrerizo, T. de Miguel, P. Pérez-Breña, A. Tenorio, G. Trallero); Instituto de Salud Carlos III National Centre of Epidemiology, Madrid (M.V. Martínez de Aragón); and Son Dureta Hospital, Palma de Mallorca, Spain (J.L. Pérez)

DOI: 10.3201/eid1411.080517

## References

1. Dowdle W, Kew O. Vaccine-derived polioviruses: is it time to stop using the word "rare"? *J Infect Dis*. 2006;194:539–41. DOI: 10.1086/506368
2. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. *Annu Rev Microbiol*. 2005;59:587–635. DOI: 10.1146/annurev.micro.58.030603.123625
3. Trallero G, Avellón A, Otero A, de Miguel T, Alonso M, Perez-Breña P. Laboratory Network within the Polio Eradication Initiative (1998–2003): six years of surveillance for acute flaccid paralysis in Spain [in Spanish]. *Enferm Infecc Microbiol Clin*. 2006;24:167–72. DOI: 10.1157/13086549
4. Casas I, Palacios GF, Trallero G, Cisterna D, Freire MC, Tenorio A. Molecular characterization of human enteroviruses in clinical samples: comparison between VP2, VP1, and RNA polymerase regions using RT nested PCR assays and direct sequencing of products. *J Med Virol*. 2001;65:138–48. DOI: 10.1002/jmv.2013
5. Casas I, Tenorio A, Echevarria JM, Klapper PE, Cleator GM. Detection of enteroviral RNA and specific DNA of herpesviruses by multiplex genome amplification. *J Virol Methods*. 1997;66:39–50. DOI: 10.1016/S0166-0934(97)00035-9
6. Yang CF, De L, Holloway BP, Pallansch MA, Kew OM. Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. *Virus Res*. 1991;20:159–79. DOI: 10.1016/0168-1702(91)90107-7
7. Cherkasova EA, Yakovenko ML, Rezapkin GV, Korotkova EA, Ivanova OE, Eremeeva TP, et al. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. *J Virol*. 2005;79:1062–70. DOI: 10.1128/JVI.79.2.1062-1070.2005
8. Karakasiliotis I, Paximadi E, Markoulatos P. Evolution of a rare vaccine-derived multirecombinant poliovirus. *J Gen Virol*. 2005;86:3137–42. DOI: 10.1099/vir.0.80823-0
9. Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. *J Virol*. 2003;77:12460–5. DOI: 10.1128/JVI.77.23.12460-12465.2003
10. Parvaneh N, Shahmohmoudi S, Tabatabai H, Zahraei M, Mousavi T, Esteghamati AR, et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. *J Clin Virol*. 2007;39:145–8. DOI: 10.1016/j.jcv.2007.04.002

Address for correspondence: Ana Avellón, National Centre of Microbiology – Diagnostic Microbiology Service, Carretera Majadahonda-Pozuelo Km.2, Majadahonda, Madrid 28220, Spain; email: aavellon@isciii.es

## Widespread Oseltamivir Resistance in Influenza A Viruses (H1N1), South Africa

**To the Editor:** Oseltamivir is the most widely used antiviral drug for influenza; it is a potent inhibitor of influenza virus neuraminidase (NA) protein (1). Until recently, oseltamivir resistance occurred in <1% of circulating viruses globally. An increased number of influenza A viruses (H1N1) with resistance to oseltamivir was first reported to the World Health Organization (WHO) by Norway in late January 2008. The viruses carried a specific histidine-to-tyrosine mutation at position 274 (H274Y; H275Y in N1

numbering system) in the NA protein that confers high-level resistance to oseltamivir (2). Further surveillance by the European Surveillance Network for Vigilance against Viral Resistance and the WHO Global Influenza Surveillance Network (GISN) showed that 16% of community isolates (0%–67% by country) of influenza A viruses (H1N1) circulating in the 2007–08 season in several other countries were also oseltamivir resistant (3). The predominant influenza subtype circulating in South Africa this winter season is H1N1. To determine whether oseltamivir-resistant viruses have spread to South Africa, we examined influenza A (H1N1) isolated during the 2008 winter season for resistance to this antiviral compound.

Specimens were obtained mainly from the National Institute of Communicable Diseases (NICD) active sentinel surveillance program in all 9 provinces. Throat or nasopharyngeal swabs were taken from patients within 48–72 hours of onset of symptoms and sent to NICD laboratories for virus isolation as described (4).

Of the H1N1 subtype viruses isolated in May and June, 23 were sent to the WHO Collaborating Centers for Reference and Research on Influenza in London and Melbourne for resistance testing (5,6). Forty-five of the viruses, which included viruses isolated in July, were tested at NICD by using a modified amplification refractory mutation system PCR (ARMS-PCR) (7). This method can simultaneously detect wild-type or mutant virus with the 274 mutation in a single PCR. Partial sequencing of the NA and hemagglutinin (HA) genes was performed to confirm the NA H274Y resistance mutation and to determine genetic drift in HA from the A/Brisbane/59/2007 virus recommended for the Northern Hemisphere 2007–08 vaccine.

At the time of resistance testing, 92 H1N1 subtype viruses had been isolated. The 23 virus isolates sent to the WHO Collaborating Centers were

<sup>1</sup>These authors contributed equally to this article.

# Paralysis Case and Contact Spread of Recombinant Vaccine-derived Poliovirus, Spain

## Technical Appendix




Figure 1. Fluctuation of capsid protein homology to Sabin 2 and viral stool excretion in serial stool samples from the paralysis case-patient (PC, left) and the asymptomatic contact with prolonged excretion (AC3, right). Time of sampling is included in the x-axis; homology percentage with respect to original Sabin 2 strain (X00595) and viral load in stools are in y-axis, left and right, respectively. Oral poliovirus (OPV) and immunotherapy doses, case detection, and death of the patient are shown in the graphic.





Figure 2. Schematic view of genome alignment of samples with respect to the original Sabin 2 strain (X00595). Nucleotide and amino acid variations common to all samples are marked. Upper lines refer to nucleotide and lower lines to amino acid changes. Underlined substitutions have been previously reported as probably associated with neurovirulence. Sabin 2/Sabin 1 recombination fragments are localized in the genome, and homology with respect to Sabin 1 is detailed in each fragment. Simplot software (<http://sray.med.som.jhmi.edu/SCSoftware/simplot>) was used to analyze recombination patterns. GenBank sequences described in this work are EU566934–EU566940 for contact samples sequences and EU566941–EU566950 for case sample sequences.



**B**

		VP2			VP3		VP1		
		NAg3b	NAg2	NAg2	NAg3a	NAg3a and 3b	NAg1	NAg2	NAg3a
	Sabin 2_AY184220	WRK	DTNATNPARN	PRT	NLTSQRK	VELSDTAHSDT	DAPTKRASRLFS	ASTEGD	KDGLT
Paralytic case	PC-M1 (Jul05)	---	-V -	---	---	-----M----	-----	-----	-----
	PC-M2 (Ago05)	---	-A -	---	---	-----	-----	-----	-----
	PC-M3 (Sep05)	---	-I -	---	---	-----	-----	-----	-----
	PC-M4 (Sep05)	---	-V -	---	---	-----	-----	-----	-----
	PC-M5 (Sep05)	---	-----	---	---	-----	-----K--	-----	-----
	PC-M6 (Oct05)	---	-----	---	---	-----	-----K--	-----	-----
	PC-M7 (Nov05)	---	-----	---	---	-----	-----K--	-----	-----
	PC-M8 (Nov05)	---	-----	---	---	-----	-----K--	-----	-----
	PC-M9 (Dec05)	---	-----	---	---	-----	-----K--	-----	-----
	PC-M10 (Jan06)	---	-----	---	---	-----	-----K--	-----	-----
Asymptomatic contact with prolonged excretion	AC2-M1 (Jul05)	---	-V -	---	---	-----M----	-----K--	-----	-----
	AC4-M1 (Jul05)	---	-----	---	---	-----	-----K--	-----	-----
	AC3-M1 (Ago05)	---	-V -	---	---	-----M----	-----K--	-----	-----
	AC3-M2 (Sep05)	---	-V -	---	---	-----M----	-----K--	-----	-----
	AC3-M3 (Nov05)	---	-----	---	---	-----	-----K--	-----	-----
	AC3-M4 (Dec05)	---	-----	---	---	-----	-----K--	-----	-----
	AC3-M5 (Jan06)	---	-----	---	---	-----	-----K--	-----	-----

Figure 3. A) Nucleotide phylogenetic tree (all bases considered), including case and contact samples. Phylogeny reconstruction method: neighbor-joining. Positions included: 1st+2nd+3rd+noncoding. Substitution model: maximum composite likelihood. Bootstrap (1,000 replicates). Divergence percentage of follow-up sequences with respect to the first isolate in each patient is shown. Divergence calculation was made with MegAlign 6.1 software (DNASTAR package). GenBank sequences described in this work are EU566934–EU566940 for contact samples sequences and EU566941–EU566950 for case sample sequences. B) Detail of predicted neutralizing antigenic sites (estimated according to previously described PV1 and 3) and amino acid changes with respect to the AY184220 Sabin 2 sequence.